Vulvar Paget disease: A national retrospective cohort study - 12/09/19
, Maaike H.M. Oonk, MD, PhD b, Helena C. van Doorn, MD, PhD c, Johan Bulten, MD, PhD d, Eleonora B.L. van Dorst, MD e, Guus Fons, MD, PhD f, Christianne A.R. Lok, MD, PhD g, Mariëtte I.E. van Poelgeest, MD, PhD h, Brigitte M.F. Slangen, MD, PhD i, Leon F.A.G. Massuger, MD, PhD a, Joanne A. de Hullu, MD, PhD aAbstract |
Background |
Vulvar Paget disease (VPD) is a rare skin disorder that is considered premalignant.
Objective |
To assess the clinical course, treatment schedules, and effect of invasion and treatment on recurrence and survival in patients with VPD.
Methods |
Data on women with VPD were retrieved from the medical files and pathology reports in all Dutch tertiary university medical centers. Disease-free survival and 5-year disease-specific survival were estimated by using Kaplan-Meier curves.
Results |
Data on 113 patients whose VPD was diagnosed between 1991 and 2016 were analyzed; 77% had noninvasive VPD. Most of the women (65%) underwent a surgical procedure. Recurrences were reported in 40%. Of the women with noninvasive VPD, 8% developed invasion. There were no disease-specific deaths reported in the women with noninvasive VPD. The 5-year disease-specific survival rate was greater than 98% in noninvasive and microinvasive VPD, but significantly worse in invasive VPD (50% [P < .0005]).
Limitations |
The main limitations of this study are its retrospective character and the fact that original pathology samples were not available for reassessment.
Conclusions |
VPD is extremely rare, and the recurrence rates are high. Most patients have noninvasive VPD, which does not affect survival and should be considered a chronic disorder with limited invasive potential. In cases of invasive disease, survival decreases significantly.
Le texte complet de cet article est disponible en PDF.Key words : extramammary, Paget disease, recurrence, survival, vulva, vulvar neoplasms
Abbreviations used : DFS, DSS, VPD
Plan
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Parts of these data were presented at the 20th European Gynaecologic Oncology Congress; Vienna, Austria; November 4-7, 2017 (abstract ESGO7-0412). |
|
| Reprints not available from the authors. |
Vol 81 - N° 4
P. 956-962 - octobre 2019 Retour au numéro
Article précédent
- Localization and age distribution of telangiectases in children and adolescents with hereditary hemorrhagic telangiectasia: A retrospective cohort study
- Cristian D. Gonzalez, Sarah D. Cipriano, Christina A. Topham, David A. Stevenson, Kevin J. Whitehead, Sheryll Vanderhooft, Angela P. Presson, Jamie McDonald
- Prevalence and determinants for xerosis cutis in the middle-aged and elderly population: A cross-sectional study
- Selma Meki?, Leonie C. Jacobs, David A. Gunn, Andrew E. Mayes, M. Arfan Ikram, Luba M. Pardo, Tamar Nijsten
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?